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he retinoblastoma (Rb) tumor suppressor controls
cellular proliferation, survival, and differentiation and
is functionally inactivated by mutations or hyper-
phosphorylation in most human cancers. Although activation
of endogenous Rb is thought to provide an effective ap-
proach to suppress cell proliferation, long-term inhibition
of apoptosis by active Rb may have detrimental consequences
in vivo. To directly test these paradigms, we targeted
phosphorylation-resistant constitutively active Rb alleles,
Rb
 
 
 
Ks, to the mouse mammary gland. Pubescent trans-
genic females displayed reduced ductal elongation and
 
cell proliferation at the endbuds. Postpuberty transgenic
mice exhibited precocious cellular differentiation and
T
 
 
 
-casein expression and extended survival of the mam-
mary epithelium with a moderate but speciﬁc effect on the
expression of E2F1, IGF1R
 
 
 
, and phospho–protein kinase
 
B/AKT. Remarkably, 
 
 
 
30% Rb
 
 
 
K transgenic females devel-
oped focal hyperplastic nodules, and 
 
 
 
7% exhibited full-
blown mammary adenocarcinomas within 15 mo. Expression
of the Rb
 
 
 
K transgene in these mammary tumors was re-
duced greatly. Our results suggest that transient activation
of Rb induces cancer by extending cell survival and that
the dual effects of Rb on cell proliferation and apoptosis
impose an inherent caveat to the use of the Rb pathway for
long-term cancer therapy.
 
Introduction
 
The retinoblastoma (Rb)* tumor suppressor exerts diverse
effects on cell growth and differentiation by modulating the
activity of transcription factors such as members of the E2F
protein family (Dyson, 1998). Rb itself is regulated at the
phosphorylation level by G1 cyclins, their associated cyclin-
dependent kinases (Cdks), and specific inhibitors (e.g.,
p16
 
Ink4a
 
) (Sherr, 2000). During most of the G1 phase of the
cell cycle, hypophosphorylated Rb interacts with E2F on
cognate binding sites and actively represses transcription of
genes required for cell cycle progression and DNA replication.
Active repression involves, at least in part, the recruitment by
Rb of chromatin-modifying enzymes such as the histone
deacetylase HDAC1 (Lai et al., 1999; Harbour and Dean,
2000a). Mitotic signals propagated through G1 cyclins in-
duce sequential phosphorylation and inactivation of Rb
(Lundberg and Weinberg, 1998). Early in G1, Cdk4/6–cyclin
D1 phosphorylates Rb at phosphoacceptor sites just down-
stream of the Rb pocket domain, which is involved in
protein–protein interaction (Harbour et al., 1999). Phos-
phorylation of these sites induces intramolecular interaction
between the negatively charged phosphate groups and basic
residues in the pocket. This intramolecular interaction in-
duces a conformation change that expels HDAC1 from Rb,
thereby relieving active transcriptional repression. Later in
G1, Cdk2–cyclin E phosphorylates Rb at Serine-567, result-
ing in dissociation of Rb from E2F, transcriptional depres-
sion of target genes, and cell cycle progression.
In addition to keeping the cell cycle in check, Rb also con-
trols cell differentiation and survival. There is evidence that
Rb can bind a plethora of differentiation factors and cooper-
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atively induce terminal differentiation and transcriptional
activation of differentiation genes in vitro (Macleod, 1999;
DiCiommo et al., 2000). In addition, Rb mutant embryos
exhibit incomplete differentiation in certain tissues and ab-
errant expression of specific markers, for example, NGF re-
ceptors during neurogenesis (Lee et al., 1994), muscle cre-
atine kinase during myogenesis (Zacksenhaus et al., 1996b),
and filensin/crystallin 
 
 
 
B during lens development (Liu and
Zacksenhaus, 2000).
A role for Rb as a survival factor is evident from the mas-
sive cell death observed in Rb-deficient mice in tissues where
Rb is normally highly expressed (Lee et al., 1994; Zacksen-
haus et al., 1996b; Jiang et al., 1997; Macleod, 1999). Fur-
thermore, in vitro, loss of Rb increases cell susceptibility to
cytotoxic drugs, whereas ectopic expression of Rb inhibits
cell death (Almasan et al., 1995; Haas-Kogan et al., 1995;
Kranenburg et al., 1996). The dual effects of Rb on cell pro-
liferation and apoptosis are mediated in some cell types by
E2F1, which controls the expression of genes required for
cell cycle progression and cell death. For example, deregu-
lated E2F1 can induce the transcription of apoptosis pro-
tease-activating factor (Apaf)-1 (Moroni et al., 2001) and
p14/19ARF, which binds and inactivates MDM2, a p53 in-
hibitor, thereby linking loss of Rb to p53-induced apoptosis
(Sherr, 2000). Consistent with these in vitro studies, apop-
tosis in Rb-deficient mice is mediated in certain tissues by
an E2F1–p53-Apaf-1–dependent pathway (Morgenbesser et
al., 1994; Macleod et al., 1996; Tsai et al., 1998; Guo et al.,
2001).
Although germ-line mutations in Rb predispose individu-
als to retinoblastoma, somatic mutations in Rb are often as-
sociated with cancer progression (DiCiommo et al., 2000).
However, in many types of cancer, such as breast cancer
(Buckley et al., 1993), other components of the Rb pathway
(i.e., Cdk4, cyclin D1, or p16
 
Ink4a
 
) are mutated preferentially
or deregulated (Weinberg, 1995). In such tumors, Rb be-
comes hyperphosphorylated and inactive, but the protein is
intact and amenable to therapeutical activation. Reactivation
of endogenous Rb in such tumors (e.g., by Cdk inhibitors)
may provide an effective approach to suppress cell prolifera-
tion. In support of this notion, introduction of phosphoryla-
tion-resistant constitutively active Rb alleles, Rb
 
 
 
Ks, into
many cell types in vitro (Mittnacht, 1998) and in vivo
(Chang et al., 1995) efficiently suppresses cell proliferation.
Figure 1. Targeted expression of constitutively 
active Rb to the mammary gland. (A) Schematic 
structure of Rb showing the pocket domain (A and 
B), relative location of 16 Cdk phosphoacceptor 
sites, and mutated residues in Rb p34 and 
Rb K11. (B) Schematic presentation of the 
MMTV-Rb p34 and MMTV-Rb K11 transgenes. 
(C) Detection of Rb K transgene by Northern blot 
analysis. The transgene has a shorter 3  UTR and 
migrates faster. (D and F) Western blots of protein 
lysates (50  g) from mammary glands of (D) 
13-wk-old or (F) 14-mo-old transgenic and wild-
type females were developed with anti-HA mono-
clonal antibody. (E) Protein lysates (1.2 mg) from 
14-mo-old transgenic and control mammary 
glands were immunoprecipitated with anti-HA 
antibodies and Western blotted with anti-Rb 
antibody. (G and H) RT-PCR analysis of the 
MMTV-Rb p34#24 and MMTV-Rb K11#29 
transgenes relative to keratin 18 in virgin (V), 
pregnant (P), lactating (Lac), and involuting (Inv) 
glands. w, weeks.   and   signs indicate the
presence or absence of reverse transcriptase. 
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Moreover, several Cdk4/6 inhibitors that target the Rb path-
way are currently in preclinical and clinical development
(Bange et al., 2001).
However, the inherent ability of Rb to suppress both cell
division and apoptosis points to a potential caveat. Activa-
tion of Rb may inadvertently protect cells, which have ac-
quired oncogenic alterations or are programmed to die in re-
sponse to normal developmental signals, from apoptosis and
lead to detrimental consequences in vivo. Of relevance here
is the observation that both overexpression and inactivation
of E2F1 induce cancer in mouse models presumably by dis-
rupting different aspects (proliferation versus apoptosis, re-
spectively) of cell physiology (Field et al., 1996; Yamasaki et
al., 1996; Pan et al., 1998; Pierce et al., 1998, 1999).
To directly address the consequences of activating Rb in
vivo, we have targeted Rb
 
 
 
K alleles to the mammary gland
of transgenic mice. We show that transgenic females initially
display ductal growth suppression but later exhibit preco-
cious differentiation, extended survival of the mammary epi-
thelium, and ultimately develop hyperplastic lesions and
mammary adenocarcinomas. The implications of these re-
sults to cancer therapy are discussed.
 
Results
 
Targeted expression of phosphorylation-resistant Rb 
alleles in the mammary gland
 
The interaction of Rb with transcription factors is dictated
by cyclin D– and cyclin E–associated kinases that phosphor-
ylate Rb in a cell cycle–dependent manner (Lundberg and
Weinberg, 1998; Mittnacht, 1998). Rb contains 16 poten-
tial phosphoacceptor sites that are distributed along the pro-
tein (Lundberg and Weinberg, 1998; Mittnacht, 1998) (Fig.
1 A). Recent evidence indicates that a cluster of serine and
threonine in exon 23 of Rb just downstream of the pocket
plays a major role in regulating Rb activity (Harbour et al.,
1999). In our study, we used two Rb
 
 
 
K alleles: Rb
 
 
 
p34
contains mutations in eight Cdk sites, four of which are
within exon 23 (Hamel et al., 1992) (Fig. 1 A). Using
Rb
 
 
 
p34 as a backbone, we generated three additional
serine/threonine to alanine substitutions in exon 23, yield-
ing Rb
 
 
 
K11, in which all phosphoacceptor sites in exon 23
are protected completely from Cdk-mediated phosphoryla-
tion (see Materials and methods) (Fig. 1 A). Due to their
resistance to phosphorylation by Cdks, the Rb
 
 
 
Ks out-
perform wild-type Rb in multiple assays and are viewed
as constitutively active, underphosphorylated, native Rb
(Hamel et al., 1992; Geng et al., 1996; Knudsen et al.,
1998; Sellers et al., 1998; Brown et al., 1999; Harbour et al.,
1999). To determine the effects of constitutive activation of
Rb on mammary gland development and cancer progres-
sion, the two Rb
 
 
 
K alleles were targeted to the mammary
gland under control of the mouse mammary tumor virus
(MMTV) long terminal repeat (Matsui et al., 1990; Fig.
1 B). Four independent MMTV-Rb
 
 
 
p34 transgenic lines
in mixed C57BL/6
 
 
 
SJL background and three MMTV-
Rb
 
 
 
K11 lines in pure FVB background were established
(Fig. 1 and Table I).
Transgenic transcripts were found in the mammary gland
and the salivary gland and spleen but not in the brain, kid-
ney, and liver (Fig. 1, C, G, and H; data not shown). The
HA-tagged Rb
 
 
 
K transgenic protein was readily detected by
immunoprecipitations and Western blots with antibodies
specific to the HA epitope (Fig. 1, D–F). However, we have
been unable so far to detect the transgenes by immunohis-
tochemistry (IHC) with our anti-HA antibodies. Reverse
transcribed (RT)-PCR analysis showed that the MMTV-
Rb
 
 
 
p34 and MMTV-Rb
 
 
 
K11 transgenes (collectively re-
 
Table I. 
 
Incidence of focal hyperplastic nodules and adenocarcinomas in transgenic mice expressing constitutively active Rb in the 
mammary gland
Transgenic line 
Number of
mammary glands analyzed
 
b
 
Number of
mammary glands with tumors
 
c
 
 
Incidence
per line 
Incidence
combined
 
%
 
MMTV-Rb
 
∆
 
p34(K8)
 
#24 38 8
 
d
 
21
#16  7 4 57
#8 16 1 6.25
#27 2 1
 
d
 
50
Total 63 14 22
Control littermates
 
a
 
50 0 0 0
 
MMTV-Rb
 
∆
 
K11 
 
 
#29 18 4
 
3d
 
22 22
Control littermates
 
a
 
70 0 0
 
WAP-Rb
 
∆
 
p34(K8) 
 
#9 7 2 28.6
#44 5 4
 
d
 
 80
#61  9 2
 
d
 
22.2
Total 21 8 38
Control littermates
 
a
 
21 0 0 0
 
a
 
Control littermates were caged together with transgenic females and analyzed in parallel.
 
b
 
Focal hyperplastic nodules were detected by whole-mount staining of the right inguinal mammary glands of 10–15-mo-old females. Palpable adenocarci-
nomas were confirmed by histopathology.
 
c
 
Numbers include both hyperplastic nodules and adenocarcinomas.
 
d
 
Indicates one full-blown mammary adenocarcinoma in this group. 
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ferred to as MMTV-Rb
 
 
 
K) were expressed throughout
mammary gland development, pregnancy, lactation, and in-
volution (Fig. 1, G and H).
 
Regulated expression of endogenous Rb during 
mammogenesis in wild-type mice
 
To relate the expression of the Rb
 
 
 
K transgenes to endoge-
nous Rb, we performed in situ hybridization and IHC anal-
yses on wild-type mammary glands (Fig. 2). Both methods
of detection revealed that endogenous Rb expression was be-
low detection level or sporadic in nulliparous females, in-
duced at mid-pregnancy, and peaked at lactation and invo-
lution (Fig. 2). Thus, compared with endogenous Rb the
Rb
 
 
 
K transgenes are expressed at a relatively high level in
nulliparous females (Fig. 1, G and H). Accordingly, we ob-
served the strongest phenotypes in nulliparous MMTV-
Rb
 
 
 
K transgenic mice as described below.
 
MMTV-Rb
 
 
 
K transgenes suppress ductal growth in 
pubescent females
 
During the ductal stage, the mammary epithelium infiltrates
the fat pad by proliferation at the terminal endbuds (TEBs)
and dichotomous side branching (Medina, 1996; Hen-
nighausen and Robinson, 1998; Cardiff et al., 2000; Silber-
stein, 2001). Whole-mount analysis of pubescent MMTV-
Rb
 
 
 
K transgenic females revealed a moderate delay in TEB
progression (Fig. 3, A–D). The suppression of ductal growth
coincided with reduced expression of proliferation cell nu-
clear antigen (PCNA), a marker for cell proliferation (Fig. 3,
F–I). On average, MMTV-Rb
 
 
 
K TEBs exhibited three- to
fourfold less PCNA-positive nuclei compared with control
wild-type littermates (Fig. 3 J). The suppression of ductal
growth was most evident at 5–7 wk of age and reduced
thereafter (Fig. 3 E). Accordingly, there were no obvious his-
tological differences between the mammary glands of trans-
genic and wild-type littermates during pregnancy and lacta-
tion, and transgenic females were able to nurse their young
and raise normal size litters (unpublished data).
 
MMTV-Rb
 
 
 
K transgenes induce alveolar outgrowth 
and precocious differentiation in nulliparous females
 
After puberty, the mammary epithelium undergoes cyclic
proliferation, limited differentiation, and cell death during
the estrous cycle (Robinson et al., 1995, 2000). Interest-
ingly, we found that fully developed nulliparous MMTV-
Rb
 
 
 
K transgenic females exhibited consistent alveolar out-
growth relative to control littermates (Fig. 4, A and B).
PCNA-staining revealed very few cycling cells in both wild-
type and transgenic mice (Fig. 4, C and D), indicating that
enlargement of the alveolar compartment was not due to
overt cellular proliferation. To test whether the alveolar out-
growth was indicative of precocious differentiation of the
mammary epithelium, we determined the expression of
 
 
 
-casein, a milk protein. Remarkably, 
 
 
 
-casein transcripts
were detected by RT-PCR in 
 
 
 
28% (10 of 35) of 9–20-wk-
old nulliparous transgenic females but only rarely and at
lower levels in wild-type littermates (Fig. 4 Q). Further-
more, IHC and Western blot analysis revealed that this milk
protein was expressed in some nulliparous transgenic but in
none of the wild-type females (Fig. 4, E, F, and R).
The alveolar outgrowth and precocious expression of
 
 
 
-casein became significantly more pronounced in 12–14-
mo-old nulliparous MMTV-Rb
 
 
 
K mice. Some transgenic fe-
males exhibited lactating-like glands that appeared distended
with milk (unpublished data). Western blot analysis revealed a
high level of 
 
 
 
-casein in these glands (Fig. 4 R). Upon histo-
logical examination, some Rb
 
 
 
K transgenic females exhibited
hyperplastic alveoli, dilated ducts, and enlarged lobules that
resembled secretory lobuloalveoli in pregnant females with
characteristic vacuoles and acinar morphology (Fig. 4, G–M).
Figure 2. Temporal expression of 
endogenous Rb during mammogenesis 
in wild-type females. (A–F) RNA In situ 
hybridization analysis of endogenous 
Rb. Shown are bright field (A, C, and E) 
and dark field (B, D, and F) micrographs 
of representative sections. (G–I) IHC of 
endogenous Rb in wild-type mammary 
glands. Arrows indicate Rb-positive 
nuclei. 
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IHC analysis demonstrated high levels of 
 
 
 
-casein expression
in the mammary gland of four out of five transgenic females
but not in control littermates (Fig. 4, N–P). RT-PCR analysis
of another group of three 18-mo-old nulliparous transgenic
and three control females revealed 
 
 
 
-casein expression exclu-
sively in the transgenic females; whey acidic protein (WAP), a
later differentiation marker, was detected in two of the three
transgenic mice (unpublished data). Thus, persistent expres-
sion of the Rb
 
 
 
K transgenes in nulliparous transgenic females
induces precocious differentiation of the mammary epithe-
lium both at the molecular and cellular levels.
 
MMTV-Rb
 
 
 
K transgenic females develop 
hyperplastic nodules
 
Intriguingly, whole-mount analysis of 10–15-mo-old MMTV-
Rb
 
 
 
K transgenic females revealed the presence of focal
hyperplastic nodules (Fig. 5). These nodules appeared in
22% of the transgenic females (18 out of 81) from indepen-
dent MMTV-Rb
 
 
 
p34 and MMTV-Rb
 
 
 
K11 lines (Table
I). Both nulliparous and multiparous transgenic females de-
veloped these lesions, indicating that pregnancy was not re-
quired for neoplastic transformation. In many cases there
were multifocal lesions per gland (Fig. 5, B, E, and F), sug-
gesting independent stochastic transformation of the mam-
mary epithelium. The incidence of hyperplastic nodules may
be underestimated because only one mammary gland per an-
imal (of the ten glands in a female mouse) was subject to
whole-mount analysis. No such lesions were observed in over
57 wild-type littermate females (Fig. 5, A and C; Table I).
 
WAP-Rb
 
 
 
p34 transgenic females also develop 
hyperplastic nodules
 
To further corroborate these observations, we targeted
Rb
 
 
 
p34 to the mammary gland under control of the WAP
promoter/3
 
  
 
UTR (Fig. 6 A). The WAP regulatory unit di-
rects linked transgenes exclusively to differentiated mammary
epithelial cells during the estrous cycle and pregnancy, and
WAP transgenes are expressed and exert phenotypic changes
in both nulliparous and multiparous females (Jhappan et al.,
1993; Sympson et al., 1994; Robinson et al., 1995). Three
WAP-Rb
 
 
 
p34 transgenic lines were established in C57BL/
6
 
 
 
SJL background. Expression of the WAP-Rb
 
 
 
p34 trans-
genes was low in all three lines, and transcripts could only be
detected during pregnancy (Fig. 6 B). Further analysis re-
vealed normal ductal elongation, pregnancy, and lactation in
WAP-Rb
 
 
 
p34 transgenic females (unpublished data). How-
ever, remarkably 38% (8 of 21) of the transgenic females
from the three independent WAP-Rb
 
 
 
p34 lines developed
focal hyperplastic nodules within 10–15 mo (Fig. 6, D and
E; Table I). As with the MMTV-Rb
 
 
 
K lines, both nullipa-
rous and parous females developed these micro lesions. No
similar lesions were found in 
 
 
 
21 wild-type littermate fe-
 
Figure 3.
 
Suppression of ductal growth in pubescent MMTV-Rb
 
 
 
K 
transgenic mice.
 
 Whole-mount staining of 5- and 7-wk-old pubescent 
MMTV-Rb
 
 
 
p34#27 (A and B) and MMTV-Rb
 
 
 
K11#29 (C and D) 
transgenic and control females. LN, lymph node. (E) The distance 
from the endbuds to the lymph nodes in 7-wk-old wild-type females 
was set at 100%. The average growth rates of endbuds in three 
transgenic females and three wild-type littermates were plotted 
against this value for each time point. PCNA staining of sections 
through endbuds of 6-wk-old MMTV-Rb
 
 
 
p34#24 (F and G) and 
MMTV-Rb
 
 
 
K11#29 (H and I) transgenic females and control 
wild-type littermates. Arrows indicate PCNA-positive nuclei. (J) 
Quantitative analysis of the relative proliferation (PCNA-positive 
nuclei) in TEBs at the indicated stages. For each time point, two 
sections each from three transgenic and three wild-type mice were 
analyzed. The average number of PCNA-positive nuclei in the 
control wild-type females for MMTV-Rb
 
 
 
K11 was set at 100%. 
Bars in E and J indicate standard deviation. 
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males (Fig. 6 C; Table I). Thus, targeted activation of Rb by
two independent promoters, MMTV and WAP, induces hy-
perplastic lesions in the mammary epithelium.
 
MMTV-Rb
 
 
 
K and WAP-Rb
 
 
 
p34 transgenic females 
develop full-blown mammary adenocarcinomas
 
A fraction (7 in 102 is 
 
 
 
7%) of the MMTV-Rb
 
 
 
p34,
MMTV-Rb
 
 
 
K11, and WAP-Rb
 
 
 
p34 transgenic females de-
veloped visible masses of 1–2 cm in diameter in their mam-
mary glands after 10–15 mo (Table I). Pathology analysis re-
vealed that these masses represented full-blown mammary
adenocarcinomas (Fig. 7; see legend for pathology). None of
 
 
 
100 wild-type littermate females in our colony developed
mammary tumors (Table I). The incidence of tumors was
highest in the MMTV-Rb
 
 
 
K11#29 line (Table I and un-
published data). We have analyzed recently two retired
MMTV-Rb
 
 
 
K11#29 transgenic and two wild-type breeders
at 20 mo of age (not included in Table I). Both transgenic fe-
males but none of the control mice developed palpable tu-
mors in several mammary glands. Histological analysis re-
vealed that each of these mammary glands contained one to
four tumors. Fig. 7 G shows one such gland with a small tu-
mor (Fig. 7 G, letter H) and several additional lesions (Fig. 7
G, letter I–K). Taken together, the results indicate that some
Figure 4. Precocious differentiation of the 
mammary epithelium in nulliparous MMTV-Rb K 
transgenic females. Whole-mount analyses of 
13-wk-old nulliparous transgenic and control 
females (A and B); PCNA staining (C and D); IHC 
for  -casein (E and F). Whole-mount hematoxylin 
staining of 14-mo-old control (G) and two nullipa-
rous transgenic (H and I) females (40 ). Note the 
dilated ducts (arrow). (J) Higher magnification 
(70 ) of the mammary gland in I, showing a 
lobuloalveolar-like structure (arrow). (K and M) 
H-E staining of mammary glands of 14-mo-old 
transgenic (M) and wild-type (K) littermate female. 
(L) H-E staining of a mammary gland from a 
17.5-d-old pregnant wild-type female (P17.5). 
Note the similarity between nulliparous transgenic 
(M) and pregnant wild-type glands (L). (N–P) IHC 
of  -casein in mammary glands of 14-mo-old 
nulliparous wild-type (N) and two transgenic 
(O and P) females. (Q) RT-PCR analysis of  -casein 
expression in 9–20-wk-old nulliparous transgenic 
and control females. (R) Western blot analysis of 
 -casein expression in transgenic (TG) and wild-
type (WT) females. 
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hyperplastic nodules in Rb
 
 
 
K transgenic mice progress into
full-fledged mammary adenocarcinomas.
 
Transgene expression is lost in mammary 
adenocarcinomas from MMTV-Rb
 
 
 
K transgenic mice
 
IHC analysis for PCNA revealed a relatively high prolifera-
tion index in the mammary adenocarcinomas derived from
MMTV-Rb
 
 
 
K and WAP-Rb
 
 
 
p34 mice (Fig. 7, L–M). This
observation has prompted us to determine whether expression
of Rb
 
 
 
K was lost during the progression of these tumors. To
this end, we analyzed the expression of the Rb
 
 
 
K transgene in
two tumor biopsies and tumor cells derived from the mammary
adenocarcinoma shown in Fig. 7 F and successfully propagated
in vitro. Remarkably, Rb
 
 
 
K transcripts were virtually lost in
both the tumor biopsies and the cultured tumor cells (Fig. 7, O
and P). These results suggest that downregulation of the trans-
gene with its inhibitory effect on cell proliferation may precede
tumor progression in MMTV-Rb
 
 
 
K transgenic mice.
 
MMTV-Rb
 
 
 
K transgenes extend the survival of 
differentiated mammary epithelial cells after single and 
multiple pregnancies
 
To directly test the effect of Rb
 
 
 
K on cell survival, we exam-
ined the first postlactational involution in MMTV-Rb
 
 
 
K
transgenic mice. During this process, the extracellular matrix
is degraded and the mammary epithelium undergoes massive
apoptosis and remodeling back to a virgin-like state. After 6 d,
most of the differentiated epithelial cells are eliminated, and
the expression of milk genes is greatly reduced (Strange et al.,
1992; Lund et al., 1996). At this stage, there were remarkably
more 
 
 
 
-casein– expressing lobuloalveoli in MMTV-Rb
 
 
 
K11
females compared with wild-type littermates (Fig. 8 D; un-
published data). RT-PCR and Western blot analyses demon-
strated a modest yet consistent elevation in the expression of
WAP and 
 
 
 
-casein in the transgenic MMTV-Rb
 
 
 
K11 fe-
males relative to control littermates (Fig. 8, F and G). In situ
apoptosis by the TdT-mediated dUtp-biotin nick end label-
ing
 
 
 
(TUNEL) assay revealed that collapsed lobules that did
not express 
 
 
 
-casein exhibited some cell death (Fig. 8, A and
B), whereas lobules that maintained 
 
 
 
-casein expression con-
tained very few apoptotic nuclei (Fig. 8, C and D). Overall,
there was a 44% reduction in apoptosis in the involuting
glands of transgenic females compared with wild-type litter-
mates (Fig. 8 E). Combined, the results suggest that the per-
sistent expression of milk genes at day 6 of involution was due
to inhibition of lobuloalveolar cell death by activated Rb.
Although Rb
 
 
 
K exerted only a moderate suppression of
apoptosis during the first involution, we asked whether it might
have a compounded effect after multiple pregnancies. To ad-
dress this possibility, we performed serial cross-section analysis
on multiparous, retired, transgenic MMTV-Rb
 
 
 
K breeders.
Interestingly, nonregressing areas with enlarged and aberrant
lobuloalveolar-like structures were detected in each of five trans-
genic females (Fig. 8, I and K) but not in five wild-type control
Figure 5. Hyperplastic nodules in the mammary gland of 
MMTV-Rb K transgenic mice. Low power views (8 ) of whole-
mount staining of #4 right inguinal mammary glands from 
13.5-mo-old nulliparous wild-type female (A) and MMTV-Rb p34#16 
transgenic littermate (B). Arrows point to hyperplastic nodules. (C 
and D) 13.5-mo-old multiparous wild-type and MMTV-Rb K11#29 
transgenic littermate gland with a hyperplastic nodule. (E and F) 
High power views of representative hyperplastic nodules (arrows) in 
independent MMTV-Rb p34 transgenic lines.
Figure 6. WAP-Rb p34 transgenic mice also develop hyperplastic 
nodules. (A) Schematic structure of the WAP-Rb p34 transgene. (B) 
RT-PCR analysis of WAP-Rb p34 expression in an 18.5-d-old 
pregnant transgenic female. (C and D) Whole-mount analysis of 
12-mo-old nulliparous wild-type (C) and WAP-Rb p34#44 trans-
genic (D) glands (8 ). (E) Representative high power view of hyper-
plastic nodules in a WAP-Rb p34#61 transgenic female (40 ). (F) 
H-E staining of cross-section through a hyperplastic nodule. Arrows 
in D and E point to hyperplastic nodules. 
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breeders (Fig. 8, H and J). These lobuloalveolar-like structures
expressed extracellular matrix as revealed by Gomori-trichrome,
a specific stain for collagen (Fig. 8, L and M), and were often
observed in multiparous transgenic females alongside hyperplas-
tic nodules and mammary adenocarcinomas (Fig. 7 K).
 
Aberrant expression of survival factors in multiparous 
MMTV-Rb
 
 
 
K transgenic breeders
 
We next determined whether the expression pattern of
known survival factors was altered in multiparous MMTV-
Rb
 
 
 
K transgenic mice. Western blot analyses of whole
mammary glands revealed that E2F1 was reduced moder-
ately; IGFR-1R  and phospho–protein kinase B (PKB)/
AKT were elevated slightly; p21
waf1/cip1 and BCl-Xl exhibited
additional faster migrating forms of unknown functions
(Fig. 8, N and P). Expression of cyclin D1 and BCl2 was
not obviously affected (Fig. 8 N; unpublished data). The ab-
errant expression of E2F1, IGFR-1R , phospho-PKB/AKT,
p21
waf1/cip1, and BCl-XL was specific to the multiparous
transgenic females and was not observed in 4-mo-old nullip-
Figure 7. Mammary adenocarcinomas in MMTV-Rb K and WAP-Rb p34 transgenic mice and loss of transgene expression. Histology of 
mammary adenocarcinomas. (A) Whole-mount staining of a palpable mammary adenocarcinoma in a 13.5-mo-old nulliparous MMTV-Rb p34#27 
transgenic female, showing the periphery of a tumor with invasion into the ducts. (B) Mammary adenocarcinoma with multiple cystic areas in 
a 12-mo-old multiparous MMTV-Rb p34#24 transgenic female. (C) Well-differentiated tubulo-acinar mammary adenocarcinoma in a 12-mo-old 
nulliparous WAP-Rb p34#44 transgenic female. (D) Well-differentiated papillary mammary adenocarcinoma with peripheral growth of 
basaloid cells and radiating keratinization in a 14-mo-old multiparous WAP-Rb p34#61 transgenic female. (E and F) Papillary mammary 
adenocarcinoma and mammary adenocarcinoma in the first and third glands, respectively, from a multiparous 18-mo-old MMTV-Rb K11#29 
transgenic female. (G) Multiple lesions in an MMTV-Rb K11#29 retired breeder. (H and K) High power magnifications of the lesions shown 
in (G). H–J are mammary adenocarcinomas; K is an enlarged lobuloalveolar-like structure. Tumors in A–F were  1–2 cm in length and significantly 
larger than H. Analysis of mammary adenocarcinomas. (L–M) PCNA staining demonstrating high mitotic index (M, arrows) in a tumor relative 
to a tumor-free gland in the same transgenic female (L). (N) Positive staining of mammary adenocarcinomas with antikeratin antibody, an epithelial 
marker. (O and P) RT-PCR analysis of transgene (O) and keratin 18 (P) expression in tumor biopsies and a derived cell line. Adenocarcinoma 
biopsies from the tumors shown in E and F (1 and 2); mammary gland from a MMTV-Rb K11 transgenic female (3); cell line derived from the 
mammary adenocarcinoma in F (4); mammary gland from a wild-type female (5). The   and – signs indicate the presence or absence of 
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arous transgenic mice (Fig. 8 O). Taken together, the results
presented in Fig. 8 suggest that Rb K suppress mammary
epithelial cell death at least in part by modulating the level
or activity of E2F1, IGFR-1R , and PKB/AKT.
Discussion
We report that targeted expression of phosphorylation-resis-
tant constitutively active Rb proteins in the mammary gland
leads to ductal growth suppression, precocious differentia-
tion, extended survival of the mammary epithelium, and
paradoxically to mammary tumors. The growth suppression
is moderate, affects ductal but not alveolar development,
and represents the only phenotype that is consistent with the
role of Rb as a tumor suppressor. The precocious differentia-
tion and mammary tumors were less expected and are dis-
cussed below.
Mechanisms of precocious differentiation in
MMTV-Rb K transgenic mice
Although the role of Rb in cell proliferation and apoptosis is
well established, it is not clear whether Rb affects terminal
differentiation directly through interaction with differentia-
tion factors or indirectly by allowing proper cell cycle exit
and cell survival (Dyson, 1998; Macleod, 1999; Harbour
and Dean, 2000b). In this study, we show for the first time
that active Rb can induce cellular and molecular differentia-
tion in vivo. Precocious differentiation of the mammary
Figure 8. Extended survival of the mammary epithelium in MMTV-Rb K transgenic mice. (A–G) Effects of activated Rb on day 6 of the first 
postlactational involution. TUNEL analysis (A and C) and  -casein IHC (B and D) were performed on adjacent sections (A and B and C and D) 
from MMTV-Rb K11#29 transgenic females at day 6 of first involution. Note the inverse correlation between the presence of apoptotic nuclei 
(A, black arrows) and the expression of  -casein (D, white arrows) in the same lobules. (E) Relative apoptosis was determined by counting 
TUNEL-positive nuclei in multiple random areas under 400  magnification. (F and G) RT-PCR and Western blot analyses of milk gene 
expression in transgenic and wild-type littermate females at day 6 of first involution. The level of milk genes was slightly higher in the transgenic 
females. (H and M) Enlarged lobuloalveolar-like structures in multiparous retired MMTV-Rb K11#29 transgenic breeders but not in control 
littermates. (H–K) H-E staining (H and I, 10 ; J and K, 40 ). (L and M) Gomori trichrome staining for collagen (L, 126 ; M, 63 ). ECM is 
present in transgenic (black arrow) but not in wild-type females (white arrow). (N–P) Western blot analyses of the indicated proteins in mul-
tiparous retired breeders (N and P) and 4-mo-old nulliparous females (O).194 The Journal of Cell Biology | Volume 156, Number 1, 2002
gland has also been described in transgenic mice overex-
pressing activated  -catenine (Imbert et al., 2001), stromo-
lysin (Sympson et al., 1994), dominant negative TGF R
(Gorska et al., 1998), E-cadherin (Delmas et al., 1999), and
in mice lacking P-cadherin (Radice et al., 1997).
The coinduction of Rb and  -casein at mid-pregnancy
(Fig. 2; unpublished data) suggests that Rb may be involved
directly in transcriptional activation of milk genes (Fig. 9 B).
This model is consistent with numerous examples, demon-
strating a required role for Rb in terminal differentiation of
certain cell types and transcriptional activation by MyoD (Gu
et al., 1993; Sellers et al., 1998; Puri et al., 2001), C/EBP
(Doppler et al., 1995), the glucocorticoid receptor (Stocklin
et al., 1996), and other factors. From a cancer treatment point
of view, the possibility that activation of Rb can induce differ-
entiation is attractive, since it may allow the development of
drugs that would propel breast tumor cells not only to exit the
cell cycle but also to terminally differentiate. However, al-
though the lack of Rb can be a limiting factor for differentia-
tion, activation of the Rb pathway may not be sufficient to
force terminal differentiation. Indeed, we have not been able
so far to detect any effect of overexpressing Rb Ks on the
 -casein promoter in transient reporter assays in Rb-positive
mammary epithelial HC11 cells (unpublished data).
In an alternative model, the Rb K transgene may induce
precocious development by extending the life span of differ-
entiated mammary epithelial cells with each estrous cycle,
hence leading to the accumulation of differentiated mam-
mary epithelial cells and milk secreting lobuloalveoli. This
“survival model” is consistent with other phenotypes ob-
served in our transgenic mice, most notably the develop-
ment of mammary tumors in the MMTV-Rb K and WAP-
Rb p34 mice. We note that the two models are not mutu-
ally exclusive, and activated Rb may promote both the onset
and survival of the differentiation state (Fig. 9 B).
Mechanisms of mammary adenocarcinoma in
MMTV/WAP-Rb K transgenic mice
Paradoxically, we found that transgene expression of consti-
tutively active Rb in the mammary gland induces mammary
adenocarcinoma. We propose that these tumors may be in-
duced in three steps. First, growth suppression by Rb K
may exert a selection pressure in favor of transforming muta-
tions that accelerate cell proliferation. Second, the suppres-
sion of cell death by the Rb K transgenes may promote the
survival and accumulation of transformed cells that would
otherwise die by apoptosis. Third, notwithstanding the lim-
ited number of tumors analyzed so far (Fig. 7 O), our results
suggest that downregulation of transgene expression may
permit rapid clonal expansion of transformed cells and the
development of full-blown mammary adenocarcinomas.
Thus, in accordance with the “survival model” described
above suppression of apoptosis by active Rb may extend the
life span of mammary epithelial cells that have partly differ-
entiated during the estrous cycle, leading to precocious dif-
ferentiation, or have acquired transforming mutations, re-
sulting in mammary adenocarcinoma (Fig. 9 B). There is
a reciprocal relationship between the phenotypes of Rb
knockout mice and E2F1 transgenic mice on the one hand
(Fig. 9 A) and the Rb K transgenic mice and E2F1-null
mice on the other hand (Fig. 9 B) (Field et al., 1996; Ya-
masaki et al., 1996; Pierce et al., 1998, 1999). This symme-
try is consistent with the antagonistic effects of Rb and E2F1
on cell cycle progression and apoptosis so that both activa-
tion and inactivation of these factors induce cancer in sus-
ceptible tissues (Fig. 9).
We note that transgenic expression of the survival factor
Bcl2 in the mammary gland is not sufficient to induce mam-
mary adenocarcinoma, although it accelerates tumorigenicity
in double transgenic mice expressing Bcl2 and Myc (Jager et
al., 1997). Similarly, a BCl2 transgene induces hyperplastic
splenic follicles, which do not progress to B cell lymphoma in
transgenic mice (McDonnell et al., 1989). In contrast, expres-
sion of BCl2 in the T cell lineage induces peripheral T cell
lymphoma (Linette et al., 1995). Activation of PKB/AKT in
the mammary gland also delays involution and promotes
mammary adenocarcinomas in conjunction with polyomavi-
rus middle T antigen but does not by itself induce tumors
(Hutchinson et al., 2001). The moderate phenotypes of the
MMTV-BCl2 and -PKB/AKT transgenic mice may reflect
Figure 9. Models for the effects of 
inactivation versus activation of the Rb 
pathway. (A) Loss of Rb leads to ectopic 
DNA synthesis, increased cell death, 
and incomplete differentiation. 
Unscheduled cell proliferation is often 
counteracted by apoptosis but in some 
cell types results in neoplastic transfor-
mation, that is, retinoblastoma in human 
and pituitary tumors in the mouse. Inhi-
bition of proapoptotic pathways (e.g., in-
activation of p53) cooperates with loss 
of Rb during cancer progression. Im-
paired differentiation in Rb-deficient 
mice may be an indirect effect due to the 
ectopic cell proliferation and apoptosis that perturb the differentiation program. Alternatively, Rb may be required for the onset of terminal differ-
entiation via direct or indirect stimulation of differentiation factors (e.g., glucocorticoid receptor, C/EBP, MyoD, etc.). (B) As shown in this study, 
activation of Rb in the mammary gland results in suppression of cell proliferation, precocious differentiation, extended survival of the mammary 
epithelium, and mammary tumors. The precocious differentiation may reflect the ability of activate Rb to extend the survival of differentiated 
cells and/or to directly promote differentiation. We propose that inhibition of apoptosis by active Rb can lead to the accumulation of oncogenic 
alterations and neoplastic transformation in susceptible tissues such as the mammary epithelium. Phosphorylation-resistant Rb alleles are oncogenic | Jiang and Zacksenhaus 195
the expression levels of the transgenes relative to the endoge-
nous proteins, or the differential sensitivity of different tissues
to perturbations in distinct apoptotic and survival pathways. 
Although unlikely, it is formally possible that by virtue of
the mutations in the Cdk phosphoacceptor sites the Rb K al-
leles have acquired activities that are not associated normally
with wild-type Rb. We note that numerous other MMTV
transgenic mice expressing dominant-active alleles have been
created, for example, neu/erbB2 (Siegel et al., 1999),  -cate-
nin (Imbert et al., 2001), TGF  (Pierce et al., 1993), and
PKB/AKT (Hutchinson et al., 2001). The Rb K alleles have
been used in diverse transcriptional and cellular contexts in
vitro and in vivo and invariably demonstrated the same albeit
superior functions as native unphosphorylated Rb (Hamel et
al., 1992; Geng et al., 1996; Knudsen et al., 1998; Sellers et
al., 1998; Brown et al., 1999; Harbour et al., 1999). Most im-
portantly, using Rb K11 as bait in exhaustive yeast two-
hybrid interactive screens of cDNA libraries from mammary
and prostate glands we have identified multiple known and
novel Rb binding factors, all of which could also bind wild-
type Rb (but not nonfunctional Rb 22 mutant; unpublished
data]). Thus, there is no evidence to our knowledge that sup-
ports the notion that the Rb K alleles are neomorphs, though
we cannot categorically rule out this possibility.
In addition to the inhibition of apoptosis, it is conceivable
that constitutive expression of Rb may promote tumorige-
nicity by inducing DNA damage. Rb can modulate the pro-
gression through S and G2 (Karantza et al., 1993; Knudsen
et al., 1998; Lukas et al., 1999; Knudsen et al., 2000), and
unscheduled activation of Rb may interfere with DNA syn-
thesis and/or DNA repair processes. Moreover, in response
to DNA damage ATM phosphorylates and stabilizes E2F1,
thereby inducing apoptosis through p53 and p73 (Irwin et
al., 2000; Lin et al., 2001). Thus, constitutive activation of
Rb may result in the accumulation of damaged DNA and
the acquisition of transforming mutations. If this model is
correct, the hyperplastic nodules in MMTV/WAP-Rb K
transgenic mice should exhibit uncharacteristically high
chromosomal anomalies, a possibility that should be tested
in future studies. Activation of endogenous Rb by Cdk in-
hibitors might induce similar chromosomal aberrations and
elicit tumors as in our transgenic mice.
The results presented in Fig. 8 suggest that inhibition of
apoptosis by active Rb involve an E2F1, IGFR1 , and PKB/
AKT pathway. Recent analysis of anchorage-independent
epithelial cell survival in vitro has indicated that the Rb–
E2F1 complex regulates PKB/AKT activity via IGF-1 and
suppresses rather than induces cell survival (Yu et al.,
2001a). These observations establish a link between Rb,
E2F1, and PKB/AKT, and conceivably this same pathway
may be used by Rb K to prolong cell survival via PKB in
the mammary epithelium (Scheid and Woodgett, 2001).
Future analysis of MMTV-Rb K:E2F1
 /  composite mice
will directly establish the role of E2F1 in the development of
neoplasia in our transgenic mice.
In contrast to the MMTV/WAP-Rb K transgenic mice,
cyclin D1–deficient mice do not succumb to mammary tu-
mors but are rather protected from a subset of oncogenic
pathways in the mammary gland (Sicinski et al., 1995; Yu et
al., 2001b). However, cyclin D1 has other targets in addi-
tion to Rb that might inhibit tumor progression in cyclin
D1
 /  mice. For example, cyclin D1 binds and stimulates
the estrogen receptor by acting as a bridging factor between
the ER and steroid receptor coactivators (Neuman et al.,
1997; Zwijsen et al., 1997, 1998). In addition, cyclin D1 in-
duces the phosphorylation of all members of the Rb protein
family, including p107 and p130, which are coexpressed
during mammary gland development (our unpublished ob-
servations), and together may mediate a strong inhibition of
proliferation in the cyclin D1
 /  mammary epithelium.
Thus, the activation of Rb cannot be equated with the loss
of cyclin D1. Furthermore, the adverse effect of the Rb
pathway may be unraveled only when activation is transient;
constitutive activation of Rb in cyclin D1–null mice may
not allow mammary epithelial cells that acquired transform-
ing mutations to proliferate and progress into full-blown
mammary adenocarcinomas. 
Implications for cancer therapy
Since deregulated proliferation is the hallmark of tumor
development, antiproliferative agents have become a ma-
jor therapeutic approach to cancer treatment. However, as
stated recently (Evan and Vousden, 2001) many growth de-
regulatory mutations have pleiotropic and tissue-specific ef-
fects on cell proliferation and apoptosis, and the therapeutic
consequences of antiproliferative agents are thus difficult to
predict.
Our results illustrate this potential problem. Although acti-
vation of Rb suppresses epithelial cell proliferation in pubes-
cent females, the Rb K transgenic mice eventually develop
breast tumors. This scenario may also occur with antiprolifer-
ative drugs in the course of cancer therapy. Systemic activa-
tion of Rb by therapeutical drugs such as Cdk inhibitors may
extend the survival of cells destined to die by apoptosis, lead-
ing to the accumulation of oncogenic alterations, clonal ex-
pansion, and ultimately cancer. Several Cdk inhibitors (e.g.,
flavopiridol) that target the Rb pathway are currently in pre-
clinical and clinical development (Bange et al., 2001). Al-
though such drugs have beneficial inhibitory effect on tumor
growth, they have also been documented to suppress apopto-
sis through Rb (Osuga et al., 2000). Our results suggest that
such drugs should be examined cautiously in long-term assays
in vivo to determine their systemic effects on tissues with high
turnover such as the mammary epithelium.
Combined, the coupled effects of Rb on cell proliferation
and apoptosis appear to render this tumor suppressor onco-
genic in certain tissues both when mutated and activated.
This inherent caveat may limit the use of certain Cdk inhib-
itors, which restrict cancer cell proliferation by activating
Rb, to short term treatments. Alternatively, inasmuch as that
cancer progression often involves the inactivation of both
Rb and p53 long-term cancer therapy may require combina-
torial drugs that would induce the Rb pathway but also an-
tagonize its survival effect.
Materials and methods
Plasmid construction and verification
pECE-HA-Rb K11. pECE-HA-Rb p34 is a mouse Rb cDNA with an HA tag
at the NH2 terminus and eight mutations in the indicated Cdk sites (a gift
from Dr. P. Hamel, University of Toronto) (Hamel et al., 1992; Fig. 1 A).196 The Journal of Cell Biology | Volume 156, Number 1, 2002
The plasmid was transformed into dcm
  bacteria to allow digestion with
StuI. The Cdk sites, S773, T814, and T819, in exon 23 of Rb p34 were
mutated to alanine by PCR-directed mutagenesis using Pfu polymerase.
Complex PCR included a forward primer (EZ52, 5 -GCACCCACA-
AAAATGGCTCCGAGATCTAGAATCTTGG) and a reverse primer (EZ53,
5 -CGGAGCCATTTTTGTGGGTGCTGGCAGACCTTCTG). The flanking
primers were as follows: a 5  primer that overlapped the StuI site at the
junction of exons 22 and 23 (EZ51, 5 -TAATAGGCCTCCTACCTTGGCAC-
CAATACCTCACATTCC) and a 3  reversed primer that overlapped the SauI
site downstream of the Rb stop codon. The  450-bp PCR product was di-
gested with StuI and SauI and cloned into pECE-HA-Rb p34, partially di-
gested with StuI, and further linearized with SauI. The PCR region in the re-
sulting pECE-HA-Rb K11 plasmid was sequenced on both strands to
confirm the site directed. The ability of Rb K11 to bind large T, localize to
the nucleus, induce the flat cell phenotype in Saos-2 cells, and suppress
E2F activation was confirmed by transfecting pECE-HA-Rb K11 DNA into
COS and Saos2 cells using standard methods (Zacksenhaus et al., 1993,
1996a).
pBS-MMTV-HA-Rb p34 and pBS-MMTV-HA-Rb K11. Briefly, the linker
in pBluescript was replaced by a double strand linker containing SacI,
NotI, XhoI, NotI, and KpnI sites, yielding pBS-EZ15/16. A 2.684-kb XhoI
fragment containing the MMTV-LTR and rabbit  -globin cassette was
transferred from mmtv-KCR plasmid (Matsui et al., 1990) provided by Dr.
Robert Coffey (Vanderbilt University, Nashville, TN) and subcloned into
pBS-EZ15/16 (pBS-MMTV). The Rb K alleles were subcloned into the
unique EcoRI site in pBS-MMTV (Fig. 1B). 
WAP-HA-Rb p34. pUC-mWAP, containing a 6.75 kb of the mouse WAP
gene (Campbell et al., 1984) cloned into a unique EcoRI, was purchased
from American Type Culture Collection. A linker KpnI, HindIII, SalI was
used to replace a 1.5 kb between the first and third exons of the WAP
gene, yielding pUC-mWAP(K, H, S). The pECE-HA-Rb p34 plasmid was
modified so that it contained a 5  HindIII and 3  SalI site, flanking the
Rb p34 coding cDNA. The HA-Rb p34 was excised as a 2.7-kb HindIII-
SalI fragment and subcloned into pUC-mWAP(K, H, S), partially digested
with HindIII and further linearized with SalI. The junction fragments at the
5  and 3  ends in WAP-HA-Rb p34 were confirmed by sequencing.
pBS-MMTV-HA-Rb p34 and pBS-MMTV-HA-Rb K11 were analyzed
in vitro to confirm the expression of the Rb alleles, interaction with large T,
and nuclear localization using antibodies specific to both Rb and HA. To
induce the MMTV-LTR promoter, COS cells were transfected with pBS-
MMTV-HA-Rb p34 or pBS-MMTV-HA-Rb K11 together with an expres-
sion plasmid for the glucocorticoid receptor (Giguere et al., 1986; Zack-
senhaus et al., 1996a), and the cells were cultured in the presence of dex-
amethasone for 36 h before analysis.
Generation, genotyping, and analysis of transgenic mice
Microinjection of 2 ng/ml DNA into pronuclei of C57BL/6 SJL or FVB
mice and generation of chimeric mice were done in the transgenic mouse
facilities at the Hospital for Sick Children and Ontario Cancer Institute.
Transgenic mice were initially identified by Southern blot hybridization
and later genotyped by PCR. Primers used for PCR of MMTV-Rb Ks were
as follows: forward primer EZ99 from exon 23 of Rb (5 -ATTTCAGAAG-
GTCTGCCAAC) and reverse primer EZ38 from the  -globin cassette (5 -
GAATAAGGAATGGACAGCAGGG); WAP-Rb p34 (EZ99 and EZ72, 5 -
CATGTCATGACACAGTCGAC). Transgenic females and control wild-type
littermates were caged together. For timed pregnancy, the morning of vag-
inal plug observation was considered as P0.5.
Southern, Northern, and Western blots, and RT-PCR analysis
Genotyping by Southern blot and PCR analyses was performed on tail
DNA as described (Zacksenhaus et al., 1996b). To detect MMTV-Rb Ks,
DNA was digested with SstI, Southern blotted, and hybridized with a 
32P-
dCTP SstI-EcoRI 1.0-kb Rb cDNA fragment from the plasmid. WAP-
Rb p34 transgene was detected after digestion of genomic DNA with
PvuII and hybridization with a 
32P-labeled KpnI-PvuII 1.9-kb probe from
WAP-Rb p34. Total RNA was isolated from mammary glands or other tis-
sues with Trizol Reagent (GIBCO BRL). For Northern blots, PolyA  RNA
samples (2  g) were resolved on 1% agarose formaldehyde gels, trans-
ferred to nylon membranes, and hybridized to a 
32P-labeled mouse Rb
KpnI-SstI 1.9 kb DNA probe. Protein lysates from mammary gland tissues
were prepared as described (Yao et al., 1999). Anti-HA monoclonal anti-
body was used directly from hybridoma supernatant. Anti-Rb G3-245 anti-
body was from Pharmingen (14001A). E2F1 (C-20), IGF1R  (sc-712), cy-
clin D1 (sc-450), BCl
 Xl (sc-7195), and p21 (sc-397) were from Santa Cruz
Biotechnology, Inc. Total AKT (#9272) and phospho-AKT (#9271) poly-
clonal antibodies were from NEB. Anti–keratin 18 was obtained from
Sigma-Aldrich. The  -casein monoclonal antibodies were a gift from Dr.
Charlotte Kaetzel (University of Kentucky, Lexington, KY) (Kaetzel and
Ray, 1984).
MMTV-Rb K transcripts were detected using reverse transcribed cDNA
(0.3–0.4  g) as a template with forward primer EZ99 and reverse primer
EZ73 (5 -TAGCCAGAAGTCAGAT-GCTC). WAP-Rb p34 was detected
with EZ99 and EZ72. Primers for WAP were forward EZ178 (5 -TAGCAG-
CAGATTGAAAGCATTATG) and reverse EZ179 (5 -GACACCGGTACCAT-
GCGTTG), for  -casein were forward EZ182 (5 -TCCTGGATCCAGC-
CTATTGCTCAAC) and reverse EZ183 (5 -AGTCCATGGGTCGAATTC), for
 -actin were forward EZ70 (5 -CTTCTACAATGAGCTGCGTG) and reverse
EZ71 (5 -TGGCATAGAGGTCTTTACGG), and for keratin 18 were forward
EZ245 (5 -TGGTCTCAGCAGATTGAGG) and reverse EZ246 (5 -CTGGT-
GTCATTAGTCTCGG). 
Whole-mount analysis
Right inguinal mammary glands (#4) were resected and flatten fixed in 4%
paraformaldehyde, treated sequentially in 100% ethanol, 100% acetone,
100% ethanol, and 95% ethanol, and stained with iron hematoxylin. The
glands were destained with 50% acidified ethanol followed by ascending
ethanol, Xylenes, and finally stored in methyl salicylate.
Histology, in situ hybridization, and TUNEL
Left inguinal mammary glands (#4) were fixed in 4% paraformaldehyde,
treated with 1 PBS, saline, 50% ethanol, and 70% ethanol (in saline), par-
affin embedded, and sections were stained with hematoxylin and eosin
(H-E) or Gomori-trichrome. In situ hybridization and TUNEL were per-
formed exactly as described (Jiang et al., 1997, 2000).
Analysis of mammary adenocarcinomas
Mammary glands with visible palpable tumors were resected, fixed in 4%
paraformaldehyde, and stained with H-E. Pathology analysis was per-
formed by Dr. Colin McKerlie (Sunnybrook Hospital, Toronto, Canada).
Some mammary tumors were cultured in  -MEM medium supplemented
with 10% FCS, 10 ng/ml EGF, and 5  g/ml insulin.
Immunohistochemistry
IHC analysis was performed with a DAKO streptABComplex/HRP kit.
PCNA monoclonal antibody (P8825; Sigma-Aldrich) was used at 1:300 di-
lution.  -casein monoclonal antibody was diluted 1:800. Rabbit antikera-
tin wide spectrum screening polyclonal antibody (DAKOZ0622) was
diluted 1:200. Rb (C-15) polyclonal antibodies from Santa Cruz Biotech-
nology, Inc. was diluted 1:50. HA monoclonal antibodies from tissue cul-
ture supernatant (at 1:20–1:200) or from Boehringer (1583816) (at 4  g/ml)
were used as in Chang et al. (1995).
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